Medical Hypotheses
Volume 59, Issue 1 , Pages 92-94 , July 2002

Prevention of the serotonin reuptake inhibitor discontinuation syndrome

  • Leo Sher

      Affiliations

    • Corresponding Author InformationCorrespondence to: Leo Sher MD, 530 West 236th Street, #3N, Riverdale, NY 10463, USA

Received 1 June 2001 ,Accepted 1 November 2001.

References 

  1. Haddad PM. Antidepressant discontinuation syndromes: clinical relevance, prevention and management. Drug Safety. 2001;24:183–197
  2. Rosenbaum JF, Fava M, Hoog SJ, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol. Psychiatry. 1998;44:75–76
  3. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J. Clin. Psychiatry. 1997;58:291–297
  4. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J. Psychiatry Neurosci. 2000;25:255–261
  5. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation. Am. J. Psychiatry. 1994;151:289
  6. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J. Clin. Psychoopharmacol. 1994;14:206–207
  7. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al.  Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br. J. Psychiatry. 1995;167:374–379
  8. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus Panel. J. Clin. Psychiatry. 1997;58(Suppl. 7):5–10
  9. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J. Clin. Psychiatry. 1997;58(Suppl 7):23–27
  10. Sher L. Selective serotonin reuptake inhibitors and discontinuation symptoms. J. Psychiatry Neurosci. 2001;26:152
  11. Hirschfield RMA, Shea MT. Mood disorders: Psychotherapy. In:  Sadock BJ,  Sadock VA editor. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. vol. 1:Philadelphia: Lippincott Williams & Wilkins; 2000;p. 1431–1440
  12. Robinson LA, Berman JS, Neimeyer RA. Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychol. Bull. 1990;108:30–49
  13. Welkowitz LA, Anxiety disorders: Psychological treatments . In:  Sadock BJ,  Sadock VA editor. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. vol. 1:Philadelphia: Lippincott Williams & Wilkins; 2000;p. 1498–1503
  14. Marks I. Behavioral psychotherapy for anxiety disorders. Psychiatry Clin. North Am. 1985;8:25–35
  15. Rosenthal NE. Diagnosis and treatment of seasonal affective disorder. JAMA. 1993;270:2717–2720
  16. Sher L. Seasonal affective disorder and seasonality: a review. Jefferson J. Psychiatry. 2000;15(1):3–11
  17. Kripke DF. Light treatment for nonseasonal depression: speed, efficacy, and combined treatment. J. Affect Disord. 1998;49:109–117
  18. DeBattista C, Schatzberg AF. Other pharmacological and biological therapies. In:  Sadock BJ,  Sadock VA editor. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. vol. 2:Philadelphia: Lippincott Williams & Wilkins; 2000;p. 2521–2531
  19. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J. Clin. Psychiatry. 1997;58(Suppl 7):28–30
  20. Generic medicine—can quality be assured? Drug Ther Bull 1997;35:9–11
  21. Wade GS. Controlled withdrawal for psychotropic drugs. Lancet. 2000;355:1822–1823
  22. Nordeng H, Lindemann , Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90:288–291
  23. Markowitz JS, De Vane CL, Liston HL, Montgomery SA. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int. Clin. Psychopharmacol. 2000;15:329–333
  24. Parker G, Blennerhassett J. Withdrawal reactions associated with venlafaxine. Aust. NZ J. Psychiatry. 1998;32:291–294
  25. Rajagopalan M, Little J. Discontinuation symptoms with nefazodone. Aust. NZ J. Psychiatry. 1999;33:594–597
  26. Sher L. Candidate gene studies in psychiatric disorders: promises and limitations. J. Psychiatry Neurosci. 2001;26:103–105

PII: S0306-9877(02)00127-5

Medical Hypotheses
Volume 59, Issue 1 , Pages 92-94 , July 2002

Article Tools